Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R mono...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Iceman89 Aug. 18 at 11:54 PM

$TLSA A research paper by H.Weiner from 2016 about anti-CD3 mAbs. Discusses Foralumab too and mentions Tiziana. Interesting overview to understand how far they have come in the last 10 years. 😎 https://www.tandfonline.com/doi/full/10.2217/imt-2016-0049

0 · Reply

LDCap Aug. 18 at 11:31 AM

$TLSA There have been no insider buys in the last few days since Early August, volume is through the roof. Someone is accumulating big time.

1 · Reply

Gegau001 Aug. 17 at 4:50 PM

$TLSA It’s holding up well—is the final push towards the 1.20 mark coming up soon? 😉

0 · Reply

Gegau001 Aug. 17 at 4:27 PM

$TLSA Added another 5k 🫤😉

0 · Reply

Gegau001 Aug. 17 at 9:42 AM

$TLSA We’re going to break the 1.20 mark today. After that, onwards to new heights 🚀🥳

0 · Reply

Iceman89 Aug. 15 at 12:33 AM

$TLSA Interesting and very through post on IL6, incl IL6R too. https://thecodon.substack.com/p/why-did-il-6-inhibition-fail?utm_source=share&utm_medium=android&r=48y7pd

0 · Reply

LDCap Aug. 14 at 5:42 PM

$TLSA take out the 20 day and 50 day and we're off. Technicals count for little in biotech but the algos will pick up. Fly baby fly

1 · Reply

rp6577 Aug. 14 at 5:36 PM

$TLSA 🔥

0 · Reply

Laurensian11 Aug. 14 at 3:08 PM

$TLSA So, looks like ATM is shut. Just awaiting the announcement that Gabrielle topped up and then onwards and upwards. Next 6 weeks (and beyond) should be extremely enjoyable. GLA

1 · Reply

JuggernautRaider Aug. 14 at 2:58 PM

Brother i got a stalker. Once i find out who they are and handle that? I can speak again. My childhood was a mess but I keep my family Safe. $TNXP 🇺🇸 I love me some $NVCR and $SEDG ☀️ $TLSA is a 💊 💎 🇮🇹, too 😜 🏀 🖤 yum yum 🍲

1 · Reply

Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares

Aug 4, 2026, 7:00 AM EDT - 15 days ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Jul 31, 2026, 7:00 AM EDT - 19 days ago

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

2026-07-22T11:30:23.000Z - 4 weeks ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

2026-06-25T11:20:37.000Z - 7 weeks ago

Tiziana Life Sciences doses last patient in intranasal foralumab trial

Jun 25, 2026, 7:00 AM EDT - 7 weeks ago

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

2026-06-15T11:42:42.000Z - 2 months ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares

May 28, 2026, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

2026-05-21T15:05:09.000Z - 3 months ago

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

May 21, 2026, 11:00 AM EDT - 3 months ago

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

2026-05-19T12:13:28.000Z - 3 months ago

Tiziana Life Sciences announces updated intranasal foralumab data

May 19, 2026, 7:00 AM EDT - 3 months ago

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

2026-05-14T13:46:05.000Z - 3 months ago

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

May 14, 2026, 7:00 AM EDT - 3 months ago

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

2026-04-16T12:01:24.000Z - 4 months ago

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

2026-02-25T12:25:15.000Z - 6 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Feb 25, 2026, 7:00 AM EST - 6 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

2026-01-20T16:20:10.000Z - 7 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Jan 20, 2026, 11:15 AM EST - 7 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 7 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

2026-01-16T12:05:16.000Z - 7 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Jan 16, 2026, 7:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 7 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

2025-12-29T13:15:44.000Z - 8 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Dec 29, 2025, 8:00 AM EST - 8 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

2025-12-19T16:05:39.000Z - 8 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Dec 19, 2025, 11:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 8 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

2025-12-17T13:50:17.000Z - 8 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Dec 17, 2025, 8:45 AM EST - 8 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

2025-12-15T20:15:08.000Z - 8 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

2025-12-15T12:35:32.000Z - 8 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Dec 15, 2025, 7:30 AM EST - 8 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

2025-12-12T19:15:11.000Z - 8 months ago

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

Dec 12, 2025, 2:10 PM EST - 8 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

2025-12-02T12:05:39.000Z - 9 months ago

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

2025-11-25T13:40:48.000Z - 9 months ago

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

Nov 25, 2025, 8:30 AM EST - 9 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 9 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 1 year ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 1 year ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 10:30 AM EDT - 1 year ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Iceman89 Aug. 18 at 11:54 PM

0 · Reply

LDCap Aug. 18 at 11:31 AM

$TLSA There have been no insider buys in the last few days since Early August, volume is through the roof. Someone is accumulating big time.

1 · Reply

Gegau001 Aug. 17 at 4:50 PM

$TLSA It’s holding up well—is the final push towards the 1.20 mark coming up soon? 😉

0 · Reply

Gegau001 Aug. 17 at 4:27 PM

$TLSA Added another 5k 🫤😉

0 · Reply

Gegau001 Aug. 17 at 9:42 AM

$TLSA We’re going to break the 1.20 mark today. After that, onwards to new heights 🚀🥳

0 · Reply

Iceman89 Aug. 15 at 12:33 AM

$TLSA Interesting and very through post on IL6, incl IL6R too. https://thecodon.substack.com/p/why-did-il-6-inhibition-fail?utm_source=share&utm_medium=android&r=48y7pd

0 · Reply

LDCap Aug. 14 at 5:42 PM

$TLSA take out the 20 day and 50 day and we're off. Technicals count for little in biotech but the algos will pick up. Fly baby fly

1 · Reply

rp6577 Aug. 14 at 5:36 PM

$TLSA 🔥

0 · Reply

Laurensian11 Aug. 14 at 3:08 PM

$TLSA So, looks like ATM is shut. Just awaiting the announcement that Gabrielle topped up and then onwards and upwards. Next 6 weeks (and beyond) should be extremely enjoyable. GLA

1 · Reply

JuggernautRaider Aug. 14 at 2:58 PM

1 · Reply

rp6577 Aug. 14 at 2:50 PM

$TLSA certainly looks like they have finished with the ATM. Enough to get to easily get post data. CEO took advantage of loading up at a cheap price. He has invested millions of his own money now. You don’t do that unless you know what is coming…. I think we see a solid rally now as we get closer to the data readout. Could be only 4-6 weeks away. Obviously the big pharma who requested early access to data via NDA will get there before us. Can certainly see a partnership announcement not long after data. Going to be a view big pharma fighting over this. I expect Sanofi is one of them $XBI $LABU

0 · Reply

nvg291_fan Aug. 14 at 2:35 PM

$TLSA I’m trying to add a bit more. I have a feeling that my patience here after seven years is about to pay off.

0 · Reply

Gegau001 Aug. 14 at 2:02 PM

$TLSA The ride begins!!! ...please fasten your seatbelts 🚀

1 · Reply

LDCap Aug. 13 at 8:01 PM

$TLSA gorgeous green candle to end the day, will they let it run now? Let's see if the raise is over. Very very bullish 💥

0 · Reply

rp6577 Aug. 13 at 7:59 PM

$TLSA ATM finished?

0 · Reply

rp6577 Aug. 13 at 6:17 PM

$TLSA someone taking full advantage of the artificially low share price at the moment

1 · Reply

LDCap Aug. 13 at 5:28 PM

$TLSA Respect to the Insiders. ATM being executed only above a dollar.

0 · Reply

Laurensian11 Aug. 12 at 8:32 PM

$TLSA Huge volume. ATM finished. Little dilution to majors. Let’s see

1 · Reply

Laurensian11 Aug. 12 at 5:14 PM

$TLSA Another monster volume day

0 · Reply

Iceman89 Aug. 11 at 7:10 PM

$TLSA Excited for the results to see what 100 microgram dosage can do and if it is better than 50.

0 · Reply

Ic0gcds000 Aug. 11 at 5:39 PM

$TLSA Why Buying Stock is Their Only Allowed "Speech"When a CEO cannot legally speak, they use their personal bank account to do the talking.By purchasing nearly 1 million shares of stock on the open market at $1.00 per share just days ago, CEO Ivor Elrifi sent the loudest message legally allowed under SEC rules. It signals to the market that he believes the current $1.00 price is a bargain compared to the private data and corporate interest he is seeing behind closed doors.looking good,.

0 · Reply

JuggernautRaider Aug. 11 at 3:53 PM

$TLSA buying opportunities all kver $CGTX $BMY $PFE 🚀

0 · Reply

Market Cap	146.35M
Revenue (ttm)	0.00
Net Income (ttm)	-18.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,623,700
Avg Vol	512,514
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	71%
Beta	0.49
Analysts	Sell
Price Target	$9.00